• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

The Chin-Up Strip 12-May-04

FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

horizonal rule

   

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration

 

Center for Devices and
Radiological Health
2098 Gaither Road
Rockville, MD 20850


MAY 12 2004

WARNING LETTER

VIA FEDERAL EXPRESS

Mr. Dale Miller
President and CEO
The Chin-Up Strip (DMI)
1820 Ridgemill Terrace
Dacula, Georgia 30019

Dear Mr. Miller

We received your letter dated January 22, 2004, in which you respond to our untitled letter of December 22, 2003. In your response, you state: "It is our intention, therefore, to file a premarket notification submission (section 510(k)) within the next 30 days claiming substantial equivalence to products already on the market for similar intended uses." Because you have not in fact filed a premarket notification submission, your continued marketing of the Chin-Up Strip® violates the Federal Food, Drug, and Cosmetic Act (the Act).

According to your Internet website, the Chin-Up Strip® is an effective treatment for mild obstructive sleep apnea. Your product is therefore a medical device as defined by section 201(h) of the Act because it is "intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease", or because it is "intended to affect the structure or any function of the body."

The law requires that manufacturers of medical devices obtain marketing approval or clearance for their products from the FDA before they may offer them for sale. This helps protect the public health by ensuring that newly-introduced medical devices are safe and effective or substantially equivalent to other devices already legally marketed in this country.

Your device is adulterated under section 501(f)(1)(B)of the Act because it is a class III device under section 513(f) of the Act and does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) or an approved application for an investigational device exemption under section 520(g).

In addition, your device is misbranded under section 502(o) of the Act because you have not submitted a section 510(k) premarket notification to the agency of your intent to introduce the device into commercial distribution. For a device requiring premarket approval, the notification required by section 510(k) of the Act is deemed satisfied when a PMA is pending before the agency. 21 C.F.R. 807.81(b).

The kind of information you need to submit in order to obtain marketing clearance is available through the Internet at http://www.fda.gov/cdrh/devadvice/3122.html. The FDA will evaluate this information and decide whether your product may be legally marketed.

This letter is not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure adherence to each requirement of the Act and regulations. Federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts.

You should take prompt action to correct this serious violation. Failure to act promptly may result in regulatory action being initiated against you by the Food and Drug Administration without further notice. These actions include, but are not limited to, seizure, injunction, and/or civil money penalties.

Please notify this office in writing within fifteen (15) working days of receipt of this letter of the specific steps you have taken to correct the noted violation, including an explanation of each step being taken to prevent the recurrence of similar violations. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed.

Your response should be sent to Tanisha A. Anthony, Consumer Safety Officer HFZ-331, Food and Drug Administration, 2094 Gaither Road, Rockville, MD 20850. If you have any questions regarding this letter, please contact Ms. Anthony at (301)594-4613.

Sincerely yours,

/s/

Timothy A. Ulatowski
Director
Office of Compliance
Center for Devices and
Radiological Health